Sonoma Pharmaceuticals Appoints Marc Umscheid as Chief Strategy and Marketing Officer
31 January 2017 - 8:05PM
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), today
announced the appointment of Marc Umscheid as chief strategy and
marketing officer. Previously, Umscheid worked at the Clorox
Company where he most recently served as senior marketing director
and business development team leader.
As CSO/CMO at Sonoma, Umscheid will direct overall global
strategy and marketing efforts while facilitating continued revenue
growth across the Sonoma Pharmaceutical product portfolio, which
includes dermatology, advanced wound care and animal healthcare
products. Umscheid will report directly to Sonoma CEO Jim
Schutz.
“Marc's expertise in global marketing and business development
at a respected consumer products company makes him a fantastic
addition to our fast-growing company,” said Jim Schutz, Sonoma CEO.
“His proven record of building brands organically as well as
vetting acquisition and partnerships opportunities makes him an
ideal fit for Sonoma Pharmaceuticals. We expect Marc to help
us focus on nearer-term profitability while continuing our
strong growth in the prescription dermatology market.”
Umscheid is a graduate of Cornell University, where he received
both a BS in business management/finance and an MBA from the
Johnson Graduate School of Management.
Sonoma Pharmaceuticals initiated a strategic turnaround plan in
April 2014, at which time the company installed new members to the
board of directors, appointed a new CEO and continued to expand the
company’s seasoned dermatology sales team. The company’s current
product portfolio consists primarily of dermatology and advanced
tissue care products based upon the company’s two proprietary and
patented technologies, Microcyn® and Lipogrid®.
About Sonoma Pharmaceuticals, Inc.Sonoma
Pharmaceuticals (formerly Oculus Innovative Sciences) is a
specialty pharmaceutical company that develops and
markets solutions for the treatment of dermatological
conditions and advanced tissue care. The company’s
products, which are sold throughout the United States and
internationally, have improved outcomes for more than five million
patients globally by reducing infections, itch, pain, scarring
and harmful inflammatory responses. The company's headquarters are
in Petaluma, California, with manufacturing operations in the
United States and Latin America. European marketing and sales
are headquartered in Roermond, Netherlands. More information can be
found at www.sonomapharma.com
Forward-Looking StatementsExcept for historical
information herein, matters set forth in this press release
are forward-looking within the meaning of the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995,
including statements about the commercial and technology progress
and future financial performance of Sonoma Pharmaceuticals,
Inc. and its subsidiaries (the “Company”). These forward-looking
statements are identified by the use of words such as “will pay,”
“expected” and “delivered,” among others. Forward-looking
statements in this press release are subject to certain risks and
uncertainties inherent in the Company’s business that could cause
actual results to vary, including such risks
that regulatory clinical and guideline developments may
change, scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances
or approvals, clinical results may not be replicated in actual
patient settings, protection offered by the
Company’s patents and patent applications may be challenged,
invalidated or circumvented by its competitors, the available
market for the Company’s products will not be as
large as expected, the Company’s common stock and warrants may be
delisted from NASDAQ, the Company’s products will not be
able to penetrate one or more targeted markets, revenues will
not be sufficient to fund further development and clinical studies,
the Company may not meet its future capital needs, the Company
may not be able to obtain additional funding, as well as
uncertainties relative to varying product formulations and a
multitude of diverse regulatory and marketing requirements in
different countries and municipalities, and other risks detailed
from time to time in the Company’s filings with the Securities and
Exchange Commission including its annual report on Form 10-K for
the fiscal year ended March 31, 2016. The Company disclaims
any obligation to update these forward-looking statements, except
as required by law.
Sonoma Pharmaceuticals®, Microcyn® Technology and Lipogrid®
Technology are trademarks or registered trademarks of Sonoma
Pharmaceuticals, Inc. All other trademarks and service marks are
the property of their respective owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
Dan McFadden
VP of Public and Investor Relations
(425) 753-2105
dmcfadden@sonomapharma.com
Sonoma Pharmaceuticals (NASDAQ:SNOAW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sonoma Pharmaceuticals (NASDAQ:SNOAW)
Historical Stock Chart
From Jul 2023 to Jul 2024